Shandong Lukang Pharmaceutical (600789.SH) subsidiary obtains drug registration certificate for Sacubitril Valsartan Sodium Tablets.
Lukang Pharmaceutical (600789.SH) announced that recently, its controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for Sacubitril Valsartan Sodium Tablets. This drug is a generic drug approved under new registration category 4, and is deemed to have passed the consistency evaluation of generic drug quality and efficacy. The drug is used for the treatment of chronic heart failure with reduced ejection fraction and essential hypertension.
Shandong Lukang Pharmaceutical (600789.SH) announced that recently, its controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for Sacubitril Valsartan Sodium Tablets. This drug is a generic drug approved under new registration category 4, and is deemed to have passed the consistency evaluation of generic drug quality and efficacy. The drug is used for the treatment of chronic heart failure with reduced ejection fraction and essential hypertension.
Related Articles
CG SERVICES (06098) repurchased 500,000 shares for HK$2.5875 million on September 22.
Farewell to the real estate label, Dexiang (00199) adopts the new abbreviation "Dexiang New Cloud Computing"
BQD (03866) has completed the issuance of RMB 500 million in financial bonds.
CG SERVICES (06098) repurchased 500,000 shares for HK$2.5875 million on September 22.
Farewell to the real estate label, Dexiang (00199) adopts the new abbreviation "Dexiang New Cloud Computing"
BQD (03866) has completed the issuance of RMB 500 million in financial bonds.
